Mostrar el registro sencillo del ítem

dc.contributor.authorWangensteen, Rosemary
dc.contributor.authorGómez Guzmán, Manuel 
dc.contributor.authorBanegas, Inmaculada
dc.contributor.authorRodríguez-Gómez, Isabel 
dc.contributor.authorJiménez, Rosario
dc.contributor.authorDuarte, Juan
dc.contributor.authorGarcía-Estañ, Joaquín
dc.contributor.authorVargas, Félix
dc.date.accessioned2024-09-16T08:52:17Z
dc.date.available2024-09-16T08:52:17Z
dc.date.issued2022-05-25
dc.identifier.citationWangensteen, R. et. al. Biomedicines 2022, 10, 1230. [https://doi.org/10.3390/biomedicines10061230]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/94466
dc.description.abstractThis study investigated the vasoactive effects of des-aspartate-angiotensin-I (DAA-I) in male Wistar rats on whole body vascular bed, isolated perfused kidneys, and aortic rings. Dose– response curves to DAA-I were compared with those to angiotensin II (Ang II). The Ang II-type-1 (AT1) receptor blocker, losartan, was used to evaluate the role of AT1 receptors in the responses to DAA-I. Studies were also conducted of the responsiveness in aortic rings after endothelium removal, nitric oxide synthase inhibition, or AT2 receptor blockade. DAA-I induced a dose-related systemic pressor response that was shifted to the right compared with Ang II. Losartan markedly attenuated the responsiveness to DAA-I. DAA-I showed a similar pattern in renal vasculature and aortic rings. In aortic rings, removal of endothelium and nitric oxide inhibition increased the sensitivity and maximal response to DAA-I and Ang II. AT2 receptor blockade did not significantly affect the responsiveness to DAA-I. According to these findings, DAA-I increases the systemic blood pressure and vascular tone in conductance and resistance vessels via AT1 receptor activation. This vasoconstrictor effect of DAA-I participates in the homeostatic control of arterial pressure, which can also contribute to the pathogenesis of hypertension. DAA-I may therefore be a potential therapeutic target in cardiovascular disease.es_ES
dc.description.sponsorshipCarlos III Health Institute of Spain grant number PI18/01715 and the Cooperative Research Network RICORS2040, RD21/0005/0015 “FEDER a way to make Europe”es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectrenin-angiotensin systemes_ES
dc.subjectdes-aspartate-angiotensin Ies_ES
dc.subjectvascular reactivityes_ES
dc.titleVasoconstrictor and Pressor Effects of Des-Aspartate-Angiotensin I in Rates_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/biomedicines10061230
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional